TippingPoint Biosciences is building the first scalable platform to model disease-specific chromatin states and systematically discover small molecules that selectively kill cells driven by aberrant epigenetic signaling, with a lead program in DIPG, a fatal pediatric brain cancer. The wedge is a screening approach that recreates the disease-state chromatin context to expose transient protein-protein interfaces and intrinsically disordered regions that only appear in pathology, targets that conventional structure-based epigenetics programs, which chase defined domains in euchromatin, cannot reach. The result is compounds that kill DIPG cells while showing no activity in non-DIPG cell lines, an early selectivity signal the team has profiled internally.
The timing is validated by a live exit comp: Jazz Pharmaceuticals acquired Chimerix for roughly $935M in April 2025, and Chimerix's dordaviprone (Modeyso) went on to win accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, the exact indication TippingPoint targets Web. Per the 2025-11-07 SOSV reference (recbqH0WgK5SgtSdU), TippingPoint's lead compound is claimed to be roughly 2x more selective than that molecule against the shared BRD4 target. StoryHouse tracked the company for nearly three years before committing $600K from Fund II into the priced Seed at a $10.0M pre-money valuation ($14.4M post), which closed 2026-02-09 after the round upsized from an earlier $3M target to $4.4M. The founder, Laura Hsieh, is a Scripps College alum, a direct Claremont network fit.
The lead indication is deliberately small: DIPG is an ultra-rare pediatric orphan cancer (150 to 300 US cases a year, roughly one-year median survival) with no curative therapy, which buys a fast regulatory path, an overall-survival endpoint, and rare-disease pricing power (Web). The near-term value case rests less on unit volume than on the Chimerix precedent, which set a roughly $935M acquisition benchmark and reimbursement expectation in the exact H3 K27M-mutant setting (Web). The broader prize is the platform: chromatin and epigenetic drug discovery is a multi-billion-dollar market growing at a mid-teens CAGR, and TippingPoint's second target, BRD4, opens a far larger TAM through pharma partnership (Web plus 2025-09-02 note, rec53hcIs7ugQs2ji).
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| TippingPoint Biosciences | Chromatin-state screening platform; recreates disease-specific context to hit transient interfaces / IDRs; DIPG lead, BRD4 second | Seed, $4.4M @ $14.4M post | — |
| Jazz Pharma (ex-Chimerix) | Dordaviprone / Modeyso, first accelerated-approval drug in H3 K27M DMG | Public; Chimerix acquired ~$935M | TP claims ~2x greater on-target selectivity vs. its molecule (recbqH0WgK5SgtSdU) |
| CAR-T / cell therapy (e.g. B7-H3) | Immunotherapy for DMG / DIPG | Academic / early clinical | Different modality; TP is an oral small molecule, not a cell therapy (Web) |
| Classical epigenetics programs | Structure-based drugs against defined domains in euchromatin | Established pharma / biotech | TP targets heterochromatin interfaces incumbents treat as undruggable |
Moat: the defensibility is a platform that recreates disease-specific chromatin context to reveal protein-protein interfaces unique to pathology, plus TippingPoint-owned composition of matter on a novel compound class layered over platform methods exclusively licensed from UCSF.
The reference exit is Jazz Pharmaceuticals' roughly $935M acquisition of Chimerix in the exact H3 K27M DMG setting (Web). Named potential acquirers surfaced in diligence include Jazz itself, a European orphan-disease pharma that missed the Chimerix deal, and Eli Lilly, already a platform partner (2025-11-07, recbqH0WgK5SgtSdU; 2026-01-12, recJowqu3jDSdgHHr). Against a $10.0M pre-money entry, a DIPG asset that reaches approval or acquisition on the Chimerix comp implies a large multiple, but the outcome is binary on preclinical and clinical execution and will require rapid Series A financing.
Matthew and Keith caught up with Laura on final round mechanics and the structure of the Eli Lilly platform partnership just ahead of close.
Fundraising status: $2.2M fully committed including StoryHouse. FreeFlow Ventures committing a $750K minimum check and helping close the round; it is an Asian American focused fund based in the US with Korea partnerships. Sontag at $250K committed with potential for more depending on round size. Additional angels writing $50-100K checks are still filling in. Exajay Ventures is a potential larger check under final diligence, which would require a decision on expanding round size.
Lilly pharma partnership structure: library access to a 150K compound library, upgraded from an initial 20K. TippingPoint selects its top 50 hits for unblinding; Lilly provides proprietary analog lists for the unblinded compounds and synthesis services for the top 15 hits. Services provided by Lilly include structural biology, cellular and in vivo testing, and medicinal chemistry support, with TippingPoint retaining the lead.
Financial terms: 2.5% royalty on revenue (definition needs clarification, net vs. gross), an option for Lilly to license back developed compounds, and no upfront payments, with services provided in-kind. Key risks: revenue definition is critical (net vs. gross is a 3x difference), sublicensing terms must offset the base royalty, and the company needs protection against restrictive licensing terms. Deal positioning: a tech-transfer arrangement, not a traditional pharma partnership.
Next steps: Laura to send the initial agreement and updates to Keith for review; introduction to Eunji Chung (Scripps alum, Silver Spur Biotech founder); update Tyler at BiocomCapDev on partnership progress; build a target list of pharma contacts for Matthew and Keith introductions; IndieBio events noted.
Laura's written answers to StoryHouse's diligence questions on the convertibles ledger, toxicity profile and the UCSF license reach-through risk.
Laura's responses to StoryHouse questions (PDF and Excel attached). On the convertibles question: the convertibles ledger is available in the data room for a line-by-line view of pre-money values.
On toxicity: epigenetic modulation has a reputation for widespread, unpredictable adverse events. TippingPoint has profiled its molecules across multiple non-DIPG cell lines, including other glioblastoma models and embryonic kidney cells, and observes no cell toxicity or activity in these non-DIPG contexts, which suggests the molecules are highly selective for killing DIPG cells. The first in vivo mouse-model readout is expected in approximately six months and is a key milestone of this financing, providing an initial assessment of tolerability and potential toxicities; non-GLP toxicology studies are planned in parallel as the company advances toward a development candidate.
On UCSF: StoryHouse noted that UCSF controls prosecution and, if the patent issues with claim 41, UCSF could make waves for approved products and at re-negotiation time with a pharma acquirer, a moderate-to-significant risk. Laura agreed with the risk, explained that she and WSGR have planned mitigation for the worst case, and, prompted by StoryHouse, decided to proactively re-open the issue as part of ongoing license negotiations, while cautioning that UCSF moves slowly. She welcomed StoryHouse's IP expertise once an investor.
Keith and Matt spoke with SOSV GP Mohan Iyer, who is breaking SOSV's usual model to co-lead the round, on rationale, terms and risks.
Mohan Iyer background and SOSV overview: General Partner at SOSV ($1.5B AUM, Fund 5 at $300M), 30+ years as a biotech operator and CEO with 70+ patents drafted, built early biotech drugs at Genentech, co-founded Diadexus. SOSV runs about 60 deals a year at $300-500K through an intensive six-month program, focused on human and planetary health, and follows on through Series A and beyond.
TippingPoint investment rationale: SOSV is breaking its usual model by leading the seed rather than bringing in a third-party VC. Laura secured exceptional UCSF license terms by approaching the chancellor directly, and recruited Savi (ex-Novartis) as a full-time medicinal chemist who worked unpaid for three months. The chromatin-biology platform comes from Geeta Narlikar's top-tier lab; the target is DIPG, a pediatric brain cancer with roughly six-month survival.
Competitive advantage vs. Chimerix: Chimerix was acquired by Jazz for $900M earlier this year; TippingPoint's lead compound is 2x more selective than Chimerix's molecule against the same BRD4 target, with a fast-track orphan pathway and a small patient population (N=7-10 for Phase I/II).
Deal structure and timeline: $3M round with a $1M co-lead (Mohan $500K plus an individual investor $500K); at $2.5M committed including Sontag Foundation ($250K); seeking StoryHouse for $300-500K; target close December 15 (originally Thanksgiving); 18-month runway to animal-model efficacy data. Use of proceeds centers on advancing the DIPG molecule to animal-model efficacy, with BRD4 platform validation for pharma partnerships, an Eli Lilly compound-library screening interest, AI integration, and two patentable compounds as a minimum viable outcome.
Key risks and mitigation: Laura's inexperience as an operator (first-time CEO); the real IP comes from small-molecule development not yet created; UCSF license reach-through under negotiation; and a high burn rate requiring quick Series A execution. Next steps: StoryHouse to receive Chimerix-vs-TippingPoint selectivity data, an updated cap table, Savi's assessment, and UCSF license clarification, with a decision timeline within days for a December closing.
Shahram Seyedin-Noor (GP) on Laura Hsieh / TippingPoint: had met the team and found it cool, but felt the full-time founder did not come across as strong enough to lead the venture, with the (non-full-time) professor doing most of the talking. Called the science exciting but early. An early cautionary reference on founder-led execution.
Source: Meeting Notes recmBJdtnPtKUN7jZ · 2023-09-06
Mohan Iyer (GP, SOSV / IndieBio) on Laura Hsieh: a strongly positive reference. He was first dollar into Laura out of UCSF, calls her the world expert in the area and a “silent killer” who navigated the UCSF license and secured orphan-disease cells from Stanford in under 30 days, and says she has beaten SOSV's expectations on hits and on the talent she has attracted. SOSV planned to co-lead, unusual for the firm.
Source: Meeting Notes recrIzGr77M5PmSWo · 2025-03-06
Scott Davis (Sontag Foundation) on Laura Hsieh / TippingPoint: increasingly comfortable with the chromatin-interaction approach and happy with how Laura delivered on hiring med-chem experts and generating promising compound series, while noting it is still very early. Sontag committed $250K and flagged that a $3M raise may be insufficient for a strong next round, favoring a slightly larger raise for a BRD4 cushion.
Source: Meeting Notes recAgYKN4zWqSUqYj · 2025-10-10